JP5599136B2 - 血管の発達を調節するための、ｅｇｆｌ７アンタゴニストを含む組成物 - Google Patents

血管の発達を調節するための、ｅｇｆｌ７アンタゴニストを含む組成物 Download PDF

Info

Publication number
JP5599136B2
JP5599136B2 JP2007508646A JP2007508646A JP5599136B2 JP 5599136 B2 JP5599136 B2 JP 5599136B2 JP 2007508646 A JP2007508646 A JP 2007508646A JP 2007508646 A JP2007508646 A JP 2007508646A JP 5599136 B2 JP5599136 B2 JP 5599136B2
Authority
JP
Japan
Prior art keywords
egfl7
antibody
antibodies
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007508646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007532685A5 (enExample
JP2007532685A (ja
Inventor
エレン フィルバロフ，
ジョー−アン エス． ホンゴ，
レオン エイチ． ザ フォース パーカー，
マイケ シュミット，
ウェイラン イエ，
Original Assignee
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック， インコーポレイテッド filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2007532685A publication Critical patent/JP2007532685A/ja
Publication of JP2007532685A5 publication Critical patent/JP2007532685A5/ja
Application granted granted Critical
Publication of JP5599136B2 publication Critical patent/JP5599136B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2007508646A 2004-04-14 2005-04-14 血管の発達を調節するための、ｅｇｆｌ７アンタゴニストを含む組成物 Expired - Fee Related JP5599136B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56205404P 2004-04-14 2004-04-14
US60/562,054 2004-04-14
PCT/US2005/013658 WO2005117968A2 (en) 2004-04-14 2005-04-14 Compositions and methods comprising an egfl7 antagonist for modulating vascular development

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011190733A Division JP2011241230A (ja) 2004-04-14 2011-09-01 血管の発達を調節するための、ｅｇｆｌ７アンタゴニストを含む組成物および方法

Publications (3)

Publication Number Publication Date
JP2007532685A JP2007532685A (ja) 2007-11-15
JP2007532685A5 JP2007532685A5 (enExample) 2008-05-29
JP5599136B2 true JP5599136B2 (ja) 2014-10-01

Family

ID=35355481

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007508646A Expired - Fee Related JP5599136B2 (ja) 2004-04-14 2005-04-14 血管の発達を調節するための、ｅｇｆｌ７アンタゴニストを含む組成物
JP2011190733A Withdrawn JP2011241230A (ja) 2004-04-14 2011-09-01 血管の発達を調節するための、ｅｇｆｌ７アンタゴニストを含む組成物および方法
JP2013196507A Withdrawn JP2013256535A (ja) 2004-04-14 2013-09-24 血管の発達を調節するための、ｅｇｆｌ７アンタゴニストを含む組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011190733A Withdrawn JP2011241230A (ja) 2004-04-14 2011-09-01 血管の発達を調節するための、ｅｇｆｌ７アンタゴニストを含む組成物および方法
JP2013196507A Withdrawn JP2013256535A (ja) 2004-04-14 2013-09-24 血管の発達を調節するための、ｅｇｆｌ７アンタゴニストを含む組成物および方法

Country Status (14)

Country Link
US (3) US20070031437A1 (enExample)
EP (1) EP1734998A2 (enExample)
JP (3) JP5599136B2 (enExample)
KR (1) KR101227817B1 (enExample)
CN (2) CN1997394B (enExample)
AU (1) AU2005249377A1 (enExample)
BR (1) BRPI0509420A (enExample)
CA (1) CA2563445C (enExample)
IL (2) IL178329A0 (enExample)
MX (1) MXPA06011851A (enExample)
NZ (1) NZ550110A (enExample)
RU (3) RU2365382C2 (enExample)
WO (1) WO2005117968A2 (enExample)
ZA (1) ZA200608615B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1734998A2 (en) 2004-04-14 2006-12-27 Genentech, Inc. Compositions and methods comprising an egfl7 antagonist for modulating vascular development
AR059851A1 (es) * 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
NZ573622A (en) 2006-06-12 2011-12-22 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
WO2008010986A2 (en) * 2006-07-17 2008-01-24 The Board Of Trustees Of The Leland Stanford Junior University Methods of modulating angiogenesis
US20090074761A1 (en) * 2007-04-24 2009-03-19 Jun Yan Therapeutic beta-glucan combinations
JP2009005584A (ja) * 2007-06-26 2009-01-15 Miyazaki Prefecture ゲル化剤、凍結保存剤、細胞保存用容器、細胞の凍結保存方法、細胞の融解方法、哺乳動物の細胞
US9549971B2 (en) * 2008-01-14 2017-01-24 Genentech, Inc. Methods for inhibiting angiogenesis using EGFL8 antagonists
WO2010034155A1 (zh) * 2008-09-25 2010-04-01 中南大学湘雅医院 一种通过检测样品中eglf7来诊断肝细胞癌的试剂盒
WO2010129904A1 (en) * 2009-05-08 2010-11-11 Genentech, Inc. Humanized anti-egfl7 antibodies and methods using same
RU2412251C1 (ru) * 2009-06-15 2011-02-20 Юрий Леонидович Дорохов Антитело против фактора роста эндотелия сосудов и способ продукции антитела в растении
CA2766403A1 (en) * 2009-07-13 2011-01-20 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
ES2765657T3 (es) * 2009-12-21 2020-06-10 Hoffmann La Roche Formulación farmacéutica de bevacizumab
WO2013061112A1 (en) 2011-10-24 2013-05-02 Centre National De La Recherche Scientifique Use of egfl7 modulators for promoting or inhibiting migration of immune cells across vascular endothelium
WO2013142961A1 (en) * 2012-03-27 2013-10-03 London Health Sciences Centre Research Inc. Egfl7 targeting and/or binding polypeptides and methods for inhibiting angiogenesis
WO2015077643A2 (en) * 2013-11-21 2015-05-28 Mfr Products, Inc. Therapeutic device to assist in myofascial release, and method of use
CN107108711B (zh) * 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
CN105543183B (zh) * 2016-01-08 2019-04-12 吴帆 人肝癌细胞Egfl8基因过表达慢病毒在制备治疗肝癌药物中的应用
CA3061505A1 (en) 2017-04-24 2018-11-01 Ohio State Innovation Foundation Recombinant egfl7, egfl7 antibodies, and uses thereof
RU2678200C1 (ru) * 2018-07-27 2019-01-24 Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии" Лекарственная пленка пролонгированного действия и способ её получения
WO2022025783A1 (ru) 2020-07-28 2022-02-03 Общество с ограниченной ответственностью "Ангиолайф" Применения комбинации генов ангиогенных и нейротрофических факторов
CN114410642B (zh) * 2021-12-31 2023-01-17 苏州大学 一种急性t淋巴细胞白血病药物靶点及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU597323B2 (en) * 1985-11-22 1990-05-31 Teijin Limited Angiogenic factor derived from blood vessel endothelial cells
EP0318488A4 (en) 1986-08-18 1990-02-26 Biota Scient Management STIMULATION OF ANGIOGENESIS AND PROMOTION OF ENDOTHELIALIZATION.
SK163598A3 (en) * 1996-05-31 1999-06-11 Scripps Research Inst Methods and compositions useful for inhibition of angiogenesis
WO2002000690A2 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1998057983A2 (en) * 1997-06-18 1998-12-23 Zymogenetics, Inc. Mammalian neuro-growth factor like protein
US20030166907A1 (en) * 1997-06-18 2003-09-04 Zymogenetics, Inc. Mammalian neuro-growth factor like protein
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US20030166107A1 (en) 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US7105640B2 (en) 1997-10-17 2006-09-12 Genentech, Inc. Anti-pro792 antibodies
US20030069178A1 (en) 1997-10-17 2003-04-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030050240A1 (en) 1997-10-17 2003-03-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6974696B2 (en) 1997-10-17 2005-12-13 Genentech, Inc. PRO853 nucleic acids
US20030039648A1 (en) 1998-09-16 2003-02-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
DK1490386T3 (da) 1998-03-10 2008-12-15 Genentech Inc Nyt polypeptid og nukleinsyrer kodende for dette
US7371836B2 (en) 1998-03-27 2008-05-13 Genentech, Inc. PRO526 nucleic acids
US7202338B2 (en) 1998-03-31 2007-04-10 Genentech, Inc. PRO731 polypeptides
US7196176B2 (en) 1998-04-01 2007-03-27 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6962797B2 (en) 1998-04-15 2005-11-08 Genentech, Inc. Nucleic acids encoding PRO615
DE19817946A1 (de) 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Uterus-Normalgewebe
AU3965799A (en) 1998-04-23 1999-11-08 Millennium Pharmaceuticals, Inc. Novel molecules of the t125-related protein family and uses thereof
US7067636B2 (en) 1998-05-06 2006-06-27 Genentech, Inc. Anti-pro 1017 antibodies
US7279553B2 (en) 1998-05-13 2007-10-09 Genentech, Inc. PRO1083 polypeptides
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7019115B2 (en) 1998-05-22 2006-03-28 Genentech, Inc. Pro1017 polypeptides
US7220835B2 (en) 1998-07-30 2007-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030203446A1 (en) 1998-10-07 2003-10-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000034477A2 (en) 1998-12-11 2000-06-15 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
AU2596700A (en) 1999-03-08 2000-09-28 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US7109292B2 (en) 1999-03-08 2006-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004507202A (ja) 1999-03-31 2004-03-11 キュラジェン　コーポレイション ポリペプチドをコードするオープンリーディングフレームを含む核酸；「ｏｒｆｘ」
KR100427563B1 (ko) 1999-04-16 2004-04-27 가부시키가이샤 후지킨 병렬분류형 유체공급장치와, 이것에 사용하는 유체가변형압력식 유량제어방법 및 유체가변형 압력식 유량제어장치
US7214656B2 (en) 1999-04-28 2007-05-08 Genentech, Inc. PRO792 polypeptides
EP1196561A2 (en) 1999-07-02 2002-04-17 Sagami Chemical Research Center HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
US20030119113A1 (en) 1999-07-20 2003-06-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
TWI265167B (en) 1999-11-29 2006-11-01 Akzo Nobel Nv 3-methylene steroid derivatives
AU2001233041A1 (en) 2000-01-25 2001-08-07 Hyseq, Inc. Novel nucleic acids and polypeptides
US7265210B2 (en) 2000-09-15 2007-09-04 Genentech, Inc. Anti-PRO9821 antibodies
ES2252461T3 (es) * 2001-02-05 2006-05-16 Innoventus Project Ab Glicoproteina rica en histidina (hrgp) para la inhibicion de la angiogenesis.
US20030224984A1 (en) * 2001-06-20 2003-12-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20030119112A1 (en) 2001-06-20 2003-06-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7202335B2 (en) 2001-12-06 2007-04-10 Genentech, Inc. PRO300 polypeptides
FR2851249A1 (fr) * 2003-02-17 2004-08-20 Commissariat Energie Atomique Nouveau facteur soluble secrete par les cellules endotheliales des vaisseaux sanguins, capable d'inhiber le recrutement des cellules perivasculaires du type musculaire lisse et ses applications
EP1734998A2 (en) 2004-04-14 2006-12-27 Genentech, Inc. Compositions and methods comprising an egfl7 antagonist for modulating vascular development

Also Published As

Publication number Publication date
US20090297512A1 (en) 2009-12-03
BRPI0509420A (pt) 2007-09-04
AU2005249377A1 (en) 2005-12-15
RU2013146239A (ru) 2015-04-27
CA2563445C (en) 2016-07-19
RU2006140081A (ru) 2008-05-20
CA2563445A1 (en) 2005-12-15
KR101227817B1 (ko) 2013-01-29
KR20070029687A (ko) 2007-03-14
ZA200608615B (en) 2008-05-28
CN102895663A (zh) 2013-01-30
NZ550110A (en) 2009-09-25
US20070031437A1 (en) 2007-02-08
JP2007532685A (ja) 2007-11-15
EP1734998A2 (en) 2006-12-27
IL178329A0 (en) 2007-02-11
WO2005117968A2 (en) 2005-12-15
JP2011241230A (ja) 2011-12-01
JP2013256535A (ja) 2013-12-26
CN1997394A (zh) 2007-07-11
RU2365382C2 (ru) 2009-08-27
IL226899A0 (en) 2013-07-31
MXPA06011851A (es) 2006-12-14
WO2005117968A3 (en) 2006-06-08
US20120003208A1 (en) 2012-01-05
CN1997394B (zh) 2012-11-28
US8790646B2 (en) 2014-07-29
RU2009114508A (ru) 2010-10-27

Similar Documents

Publication Publication Date Title
US8790646B2 (en) Compositions and methods for modulating vascular development
DE60036945T2 (de) Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen
EP1072273B1 (en) Vascularization inhibitors
JP2009539403A (ja) 癌を診断および処置するための組成物および方法
EA018260B1 (ru) Антитела к дельта-подобному лиганду 4 человека и их применение
US9549971B2 (en) Methods for inhibiting angiogenesis using EGFL8 antagonists
JP2007505131A (ja) Ｗｉｓｐアンタゴニストの使用方法
AU2011211408A1 (en) Compositions and methods comprising an EGFL7 antagonist for modulating vascular development
HK1180964A (en) Compositions and methods comprising an egfl7 antagonist for modulating vascular development
HK1149205B (en) Methods for inhibiting angiogenesis using egfl8 antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110603

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110701

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110802

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110901

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120613

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120802

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140812

R150 Certificate of patent or registration of utility model

Ref document number: 5599136

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees